Altfest L J 13F: Exits Danaher (DHR) Stake
Key Points
- Altfest L J sold 15,425 shares of Danaher Corporation, reducing its holdings to zero and marking a 100% decrease in its position.
- Danaher Corporation's stock recently traded around $232.10, which is about equal to its closing price of $232.00 on the filing date.
- Analysts maintain a strong buy consensus on Danaher, with a mean price target of $259.90, suggesting potential for growth despite the recent sell-off.
Get Danaher text alerts
We text you when insiders, Congress, analysts or big funds move on $DHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
Altfest L J sold 15,425 shares of Danaher Corporation (DHR), exiting its entire position in a filing on October 27, 2026. The information comes from the fund's latest Form 13F filing with the SEC.
DHR
Danaher Corporation
What Changed in Altfest L J's Danaher Position
Altfest L J cut its stake in Danaher Corporation entirely, selling all 15,425 shares it previously held. This represents a 100% decrease in its position, which was valued at $234,241,778 before the sale.
Where Danaher Fits in Altfest L J's Portfolio
With this sale, Danaher Corporation no longer appears in Altfest L J's portfolio. The fund had ranked 318 among its reported holdings, indicating that Danaher was a smaller part of its overall investment strategy.
Other Institutional Activity in Danaher
Several other funds have adjusted their positions in Danaher. Coronation Fund Managers grew its stake by 65,637 shares, bringing its total to 129,602 shares worth about $28.7 million. Capital International Investors also increased its holdings, adding 1,489,759 shares for a total of 15,504,420 shares valued at approximately $3.6 billion.
Danaher Corporation Stock Up 0.7%
Danaher Corporation's stock recently traded around $232.10, which is about equal to its closing price of $232.00 on October 27, 2026. The stock is currently above its 50-day moving average by about 7.1% and its 200-day moving average by 15.4%, suggesting a strong performance relative to these benchmarks.
Recent Earnings
For the trailing twelve months, Danaher reported a revenue of $25.6 billion and an EPS of $6.04. The next earnings report is scheduled for January 27, 2027, which will provide further insights into the company's performance.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Analysts Set New Price Targets
On October 22, 2026, several firms maintained their ratings on Danaher. Citigroup and TD Cowen both have a Buy rating with a price target of $270. Barclays and JP Morgan also maintained their Overweight ratings with targets of $260 and $270, respectively. The consensus among analysts remains a strong buy with a mean price target of about $259.90.
About Danaher Corporation
Danaher Corporation designs and manufactures a wide range of professional, medical, and industrial products. The company operates in various sectors, including biotechnology, life sciences, and diagnostics. This recent sell-off by Altfest L J may indicate a shift in investment strategy, especially as the company continues to perform well in the market.
Bottom Line
Investors should keep an eye on Danaher's upcoming earnings report on January 27, 2027, as well as any further filings from Altfest L J. The current market dynamics and analyst ratings suggest that there may still be opportunities for growth in Danaher's stock despite the recent changes in institutional holdings.
Related Filing Alerts
Source: Altfest L J's 13F filing on $DHR (Oct 27, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts